Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MACH: Machkhan vs Co-administration in Hypertension
NCT03231982Phase 4Unknown
- Sponsor
- HK inno.N Corporation
- Start
- Apr 2017
- Primary completion
- Apr 2019
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in essential hypertension (2 arms), sponsored by HK inno.N Corporation. Primary endpoint: Change in sitting Systolic Blood Pressure from baseline at 8 weeks. Status: unknown.
02
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT03231982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03231982.